Vamshi Alla, Krishna; Praveen Kumar, Gannu; Cheruku, Vishvasa; Jannu, Anand; Kumari Bairi, Chaitanya
May 2011
International Journal of Pharmaceutical Sciences Review & Resear;May/Jun2011, Vol. 8 Issue 1, p21
Academic Journal
Lamivudine is a Nucleoside Reverse Transcriptase Inhibitor (NRTI), licensed for the treatment of HIV, and chronic Hepatitis B. The pharmacokinetic data of Lamivudine shows that, frequent administration for a prolonged period of time (lifelong in AIDS and for one year in hepatitis patients) is necessary to maintain constant therapeutic drug levels in the body, in case of AIDS-the dose is 150 mg twice daily (i.e. multiple times a day) in the form of conventional oral tablets. But the long-term AIDS therapy with the conventional tablets of Lamivudine found to have some drawbacks, such as adverse side effects (sometimes severe) resulting from accumulation of drug in multi-dose long-term therapy; poor patient compliance; and high cost. Designing of controlled and sustained release once-daily formulations of Lamivudine can overcome these problems, and maintaining of systemic drug levels consistently above its target antiretroviral concentration throughout the course of the treatment (which is crucial for the success of AIDS therapy) is also possible with these approaches. This review briefly discusses about the novel dosage forms like controlled release matrix tablets, floating tablets, nanoparticles, microparticles, liposomes, and niosomes; which may possibly suitable for the controlled and/or sustained release of Lamivudine and thus, useful in developing the more effective AIDS therapy with very less or no adverse side effects.


Related Articles

  • Lamivudine.  // AHFS Consumer Medication Information;Sep2019, p1 

    Lamivudine (Epivir) is used in combination with other medications to treat human immunodeficiency virus (HIV) infection in patients with acquired immunodeficiency syndrome (AIDS). Lamivudine is not a cure and may not decrease the number of HIV-related illnesses. Lamivudine does not prevent the...

  • Severe skin rash with lamivudine in HIV infected patients:Some unusual case reports. Modak, Dolanchampa; Guha, Subhasish Kamal // Indian Journal of Pharmacology;May/Jun2013, Vol. 45 Issue 3, p298 

    Lamivudine (3TC) is a nucleoside reverse transcriptase inhibitor (NRTI) licensed for as a first line drug in Human immunodeficiency virus (HIV) infection and also in the treatment of hepatitis B. It is relatively nontoxic in nature and potentiates the antiviral effects of other NRTIs like...

  • Mechanisms involved in the Abacavir-mediated hypersensitivity syndrome. Llano, Anuska; Brander, Christian // Cell Research;Dec2012, Vol. 22 Issue 12, p1637 

    The potentially life-threatening adverse reactions to Abavacir (ABC), a nucleoside analog reverse transcriptase inhibitor for the treatment of HIV infection, have been known for several years to be limited to individuals expressing the HLA-B57:01 gene. Why the ABC hypersensitivity syndrome is...

  • Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment. Pefura Yone, Eric W.; Kengne, André P. // HIV/AIDS - Research & Palliative Care;2012, Vol. 4, p181 

    An extended-release formulation of nevirapine (NVP-XR) has been developed with the aim of simplifying antiretroviral treatment regimens and improving patients' adherence with a single daily intake. The VERxVE and TRANxITION clinical trials have demonstrated the noninferiority of NVP-XR compared...

  • Emtricitabine compared with lamivudine may preserve future therapeutic options in HIV-1-infected children. Frange, Pierre; Blanche, Stephane; Chaix, Marie-Laure // Journal of Antimicrobial Chemotherapy (JAC);Nov2013, Vol. 68 Issue 11, p2694 

    The article discusses a study on the use of emtricitabine as a treatment for HIV-1-infected children compared to lamivudine. Emtricitabine is a nucleoside reverse transcriptase inhibitor that is related to lamivudine. The authors recommend emtricitabine-based first line combinations for...

  • Azvudine, A Novel Nucleoside Reverse Transcriptase Inhibitor Showed Good Drug Combination Features and Better Inhibition on Drug-Resistant Strains than Lamivudine In Vitro. Wang, Rui-Rui; Yang, Qing-Hua; Luo, Rong-Hua; Peng, You-Mei; Dai, Shao-Xing; Zhang, Xing-Jie; Chen, Huan; Cui, Xue-Qing; Liu, Ya-Juan; Huang, Jing-Fei; Chang, Jun-Biao; Zheng, Yong-Tang // PLoS ONE;Aug2014, Vol. 9 Issue 8, p1 

    Azvudine is a novel nucleoside reverse transcriptase inhibitor with antiviral activity on human immunodeficiency virus, hepatitis B virus and hepatitis C virus. Here we reported the in vitro activity of azvudine against HIV-1 and HIV-2 when used alone or in combination with other antiretroviral...

  • Lamivudine monotherapy as a holding regimen in the era of antiretroviral treatment resistance. Meyer, J. C.; Schellack, N. B. // South African Pharmaceutical Journal;2015, Vol. 82 Issue 9, p43 

    Limited treatment options are available for HIV-infected paediatric patients that are virologically failing combination antiretroviral treatment (cART). This paper describes the use of lamivudine monotherapy (LM) as a holding strategy for the short-term treatment of specific multi-drug resistant...

  • Neurological and Psychiatric Adverse Effects of Antiretroviral Drugs. Abers, Michael; Shandera, Wayne; Kass, Joseph // CNS Drugs;Feb2014, Vol. 28 Issue 2, p131 

    Antiretroviral drugs are associated with a variety of adverse effects on the central and peripheral nervous systems. The frequency and severity of neuropsychiatric adverse events is highly variable, with differences between the antiretroviral classes and amongst the individual drugs in each...

  • NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS.  // Complete Guide to Prescription & Nonprescription Drugs 2012;2012, p610 

    The article presents information on nucleoside reverse transcriptase inhibitors, including their dosage, usage, adverse reactions, side effects, precautions when administering, and possible interaction with other drugs.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics